Catalent (NYSE:CTLT) Now Covered by StockNews.com

StockNews.com began coverage on shares of Catalent (NYSE:CTLT) in a research report sent to investors on Friday morning. The firm issued a hold rating on the stock.

A number of other brokerages have also weighed in on CTLT. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Robert W. Baird reissued a “neutral” rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Eight research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

Shares of NYSE CTLT opened at $63.48 on Friday. The stock has a fifty day moving average price of $60.82 and a 200 day moving average price of $59.51. Catalent has a 1-year low of $41.15 and a 1-year high of $63.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The company has a market cap of $11.52 billion, a PE ratio of -28.09, a P/E/G ratio of 2.70 and a beta of 1.15.

Catalent (NYSE:CTLT) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.10) EPS. Sell-side analysts forecast that Catalent will post 0.78 EPS for the current year.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

A number of large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in Catalent by 1.5% in the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock valued at $451,315,000 after purchasing an additional 113,095 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after buying an additional 2,299,784 shares during the last quarter. Alpine Associates Management Inc. boosted its stake in shares of Catalent by 3.4% during the 3rd quarter. Alpine Associates Management Inc. now owns 2,131,126 shares of the company’s stock valued at $129,082,000 after buying an additional 69,875 shares during the last quarter. Bank of Montreal Can grew its position in shares of Catalent by 181.5% during the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company’s stock worth $109,388,000 after buying an additional 1,169,044 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Catalent by 5.1% in the second quarter. Marshall Wace LLP now owns 1,792,951 shares of the company’s stock worth $100,818,000 after buying an additional 86,533 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.